Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses

Introduction Dolutegravir/lamivudine (DTG/3TC) was first approved by the US Food and Drug Administration in 2019 for the treatment of antiretroviral therapy (ART)-naive people with HIV-1 based on results from the pivotal GEMINI-1/GEMINI-2 trials. Around that time, immediate initiation of treatment u...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Infectious diseases and therapy Ročník 13; číslo 4; s. 875 - 889
Hlavní autoři:	Benson, Paul, Kuretski, Jennifer, Donovan, Cynthia, Harper, Gavin, Merrill, Deanna, Metzner, Aimee A., Mycock, Katie, Wallis, Hannah, Brogan, Andrew P., Patarroyo, Jimena, Oglesby, Alan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Cheshire Springer Healthcare 01.04.2024 Springer Springer Nature B.V Adis, Springer Healthcare
Témata:	Analysis Antiretroviral agents Antiretroviral drugs Antiviral agents Art history Care and treatment Dolutegravir Drug approval Drug therapy Failure analysis FDA approval Highly active antiretroviral therapy HIV (Viruses) HIV testing HIV-1 Infectious Diseases Internal Medicine Lamivudine Medicine Medicine & Public Health Original Research Real-world evidence RNA Social service Test-and-treat Viral load United States > US HIV-1 Lamivudine Viral load Test-and-treat Dolutegravir Real-world evidence
ISSN:	2193-8229, 2193-6382
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!